Malignant Respiratory System Neoplasm

A 75-year old woman presented with lung adenocarcinoma (stage IVA) to which next-generation sequencing revealed METex14del. The patient was put on crizotinib (500 mg/day) and showed partial response f… (full text at CIViC)

PMID 33533182 · Takamori et al., 2021 · Open in CIViC

A 60-year old male (smoker: 38 pack-years presented with stage IIB lung adenocarcinoma. After receiving an upper lobectomy, the left lobar lymph node was pathologically positive and received cisplati… (full text at CIViC)

PMID 37228358 · Onodera et al., 2023 · Open in CIViC

A 65-year old male (non-smoker) presented with advanced sarcomatoid non-small-cell lung cancer harboring a MET exon 14 skipping mutation with elevated PDL1 levels (tumor proportion score of 80%). Afte… (full text at CIViC)

PMID 35871685 · Gonugunta et al., 2022 · Open in CIViC

A 58-year old male (non-smoker/non-drinker) was diagnosed with metastatic adenocarcinoma with sarcomatoid components. A tissue sample revealed a MET exon 14 skipping mutation and the patient was treat… (full text at CIViC)

PMID 35110965 · Gu et al., 2022 · Open in CIViC

An 83-year old male (smoker) was diagnosed with adenocarcinoma of right upper lung. Next-generation sequencing (NGS) analysis found MET exon 14 skipping mutation and MET C526F mutation and the patient… (full text at CIViC)

PMID 31055074 · Jin et al., 2019 · Open in CIViC

A 70-year old male (former smoker: 50 pack-years) was diagnosed with stage Ib lung adenocarcinoma. Next-generation sequencing showed a MET exon 14 skipping mutation, confirmed later with RNA analysis.… (full text at CIViC)

PMID 34994615 · Pruis et al., 2021 · Open in CIViC

A 61-year old male (non-smoker) was diagnosed with sarcomatoid non-small-cell lung cancer (CK+, TTF1+, and vimentin+). Genomic profiling showed two MET alterations that showed exon 14 skipping mutatio… (full text at CIViC)

PMID 26709483 · Lee et al., 2015 · Open in CIViC

38 patients with locally advanced or metastatic non-small-cell lung cancer were divided into two groups, Part A had c-MET overexpression and Part B had MET exon 14 skipping mutation. Part A was given … (full text at CIViC)

PMID 37041472 · Hu et al., 2023 · Open in CIViC

A 67-year old Asian female (non-smoker) diagnosed with stage IV metastatic lung adenocarcinoma and also presented with superior vena cava syndrome and weight loss. Ultrasound-guided biopsy of lymph no… (full text at CIViC)

PMID 27666659 · Ou et al., 2017 · Open in CIViC

A 71-year old male (non-smoker) was diagnosed with stage IV lung adenocarcinoma. Genomic profiling of a lung cavity showed MET exon 14 skipping mutation and the patient began crizotinib therapy. Treat… (full text at CIViC)

PMID 28629543 · Schrock et al., 2017 · Open in CIViC

Analysis of 32 patients with lung neoplasms from the University of Chicago Medical Center. Results yielded high c-MET levels in 100% of all non-small-cell lung cancer samples (n=23) and 89% of all cel… (full text at CIViC)

PMID 15735036 · Ma et al., 2005 · Open in CIViC

Patient small-cell lung cancer cells with c-MET juxtamembrane mutations (R988C or T1010I) were shown to have increased tyrosine phosphorylated cellular proteins such as paxillin, a focal adhesion cyto… (full text at CIViC)

PMID 14559814 · Ma et al., 2003 · Open in CIViC

A 69-year old male (50 year history of smoking) was diagnosed with stage IIIC lung adenocarcinoma after a 13.2 x 8.8 x 9 cm mass with multiple lymph node metastases were found in a CT scan. Next-gener… (full text at CIViC)

PMID 29381967 · Tan et al., 2017 · Open in CIViC

A homozygous splice site point mutation at the donor site of Met Exon 14 (G>T at +1 position; Figure 1A, and Figure S1a) was identified in the H596 lung cancer cell line. RT-PCR of RNA demonstrated sk… (full text at CIViC)

PMID 16397241 · Kong-Beltran et al., 2006 · Open in CIViC

A 72-year old man (non-smoker) was diagnosed with lung adenocarcinoma and developed multiple recurring brain and lung metastases. Systemic chemotherapy was administered, and genomic analysis of the su… (full text at CIViC)

PMID 34695875 · Kunimasa et al., 2021 · Open in CIViC

A 83-year old woman presented with sarcomatoid squamous cell carcinoma. Next-generation sequencing revealed a MET exon 14 skipping mutation (c.3028+3A>G) and the patient was treated with crizotinib (2… (full text at CIViC)

PMID 36147925 · Sun et al., 2022 · Open in CIViC

In one patient with metastastic lung adenocarcinoma harboring a c-Cbl binding site alteration (Y1021H) deomonstrated radiological response to crizotinib and a PFS of 10.6 months.

PMID 31809977 · Wiesweg et al., 2020 · Open in CIViC

A 61-year old female (non-smoker) was diagnosed with stage IIIb adenocarcinoma of the left lung. Next-generation sequencing of the peripheral blood revealed MET Y1003S mutation. The patient was treate… (full text at CIViC)

PMID 30885356 · Miao et al., 2019 · Open in CIViC

MIR21 expression was assessed in 58 NSCLC patient samples by real-time PCR. There was a significant association between MIR21 expression and platinum sensitivity (p=0.007). MIR21 expression was signif… (full text at CIViC)

PMID 22237007 · Gao et al., 2012 · Open in CIViC

MIR21 expression was assessed in 58 NSCLC patient samples by real-time PCR and a significant association between MIR21 expression and platinum sensitivity was found (p=0.007). To directly test the rol… (full text at CIViC)

PMID 22237007 · Gao et al., 2012 · Open in CIViC

In a retrospective cohort of metastatic lung adenocarcinoma from the BATTLE-2 trial (n = 72), patients with CDKN2A and MTAP co-underexpression tumors (n = 26; representative for 9p21 loss) demonstrate… (full text at CIViC)

PMID 35379845 · Alhalabi et al., 2022 · Open in CIViC

A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC)

PMID 28490518 · Sen et al., 2017 · Open in CIViC

In a cohort of 178 patients with lung squamous cell carcinoma from The Cancer Genome Atlas, high neoantigen burden was significantly associated with improved disease-free survival compared with low ne… (full text at CIViC)

PMID 30824826 · Chae et al., 2019 · Open in CIViC

Approximately 2% of NSCLCs had RASA1 truncating mutations, and this alteration was statistically, but not completely, mutually exclusive with known activating EGFR (p=0.02) and KRAS (p=0.02) mutations… (full text at CIViC)

PMID 29127119 · Hayashi et al., 2018 · Open in CIViC

In a phase 2 trial, patients with squamous cell lung carcinoma harboring NFE2L2 mutation were treated with oral TORC1/2 inhibitor TAK228. ORR 25% (1 PR, 3 SD, 0 PD).

Open in CIViC

In an NCI-CTEP phase 2 trial, patients with squamous cell lung carcinoma with NFE2L2 mutations were treated with TORC1/2 inhibitor TAK-228. The response rate was 29% (2/7）and disease control rate was … (full text at CIViC)

Open in CIViC

In a retrospective study of stage IV NSCLC patients treated with first-line platinum doublet chemotherapy (n = 103; 51 KEAP1/NFE2L2/CUL3-mutant, 52 WT), mutations in NFE2L2, KEAP1, or CUL3 were associ… (full text at CIViC)

PMID 31548347 · Jeong et al., 2020 · Open in CIViC

NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

A 65-year old white male (non-smoker) developed recurrent metastatic NSCLC 17 months after lobectomy for stage IA disease. Genomic profiling showed MET exon 14 skipping mutation without MET amplificat… (full text at CIViC)

PMID 27693535 · Klempner et al., 2017 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK T1151M co-mutation, demonstrated resistance to crizotinib treatment (IC50: 346.65… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

Higher expression of NQO1 was correlated with decreased cytotoxicity of amrubicin (amrubicinol is the active metabolite) in 27 NSCLC and SCLC cell lines. siRNA knockdown of NQO1 (in two cell lines) i… (full text at CIViC)

PMID 21964527 · Takakuwa et al., 2011 · Open in CIViC

The presence of NQO1 C609T SNP (rs1800566) was associated with decreased protein expression and higher amrubicin sensitivity in 29 NSCLC and SCLC cell lines. 15 of these cell lines were genotyped for … (full text at CIViC)

PMID 21964527 · Takakuwa et al., 2011 · Open in CIViC

In an in vitro study, a PC-9 cell line expressing NRAS Q61K mutation demonstrated decreased sensitivity to erlotinib treatment compared to PC-9 cells expressing NRAS wild-type. Sensitivity was determi… (full text at CIViC)

PMID 22773810 · Ohashi et al., 2012 · Open in CIViC

NRAS mutations define a distinct subset of lung cancers (∼1%) with potential sensitivity to MEK inhibitors. Although NRAS mutations are more common in current/former smokers, the types of mutations ar… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations and 5/6 were sensitivi… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations and 5/6 were sensitivi… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

In a clinical study of 49 patients, 10 patients with Non-Small Cell Lung Cancer (NSCLC) and wild-type NRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

In this study, an NRG1 overexpressing PC9HRG cell line was resistant to erlotinib because of active HER3 signalling. Treatment with afatinib was effective in disrupting signaling and cell line viabili… (full text at CIViC)

PMID 26418897 · Yonesaka et al., 2015 · Open in CIViC

In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decrea… (full text at CIViC)

PMID 23390248 · Hegde et al., 2013 · Open in CIViC